Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with high unmet medical needs.
With its unique Reverse Translational Medicine™ platform, Neurimmune creates recombinant human-derived monoclonal antibodies with biophysical characteristics closely resembling those occurring in healthy elderly. These antibodies display unique properties such as target selectivity, superior pharmacodynamics and low immunogenicity, resulting in superior risk profiles and excellent efficacy.
Neurimmune’s pipeline comprises programs for a broad variety of disease related targets and specific target conformations. These include misfolded, oligomeric, fibrillar or post-translationally modified forms of disease-associated proteins as well as physiological conformations involved in major disease pathways.
Neurimmune partnered its lead program in Alzheimer’s disease with Biogen in 2007. Aducanumab (BIIB037) is a recombinant human monoclonal antibody targeting Abeta aggregates that are thought to play a role in the neurodegenerative process in Alzheimer’s disease. Aducanumab (BIIB037) is currently being investigated in Phase 3 studies in patients with prodromal and mild Alzheimer’s disease.
Neurimmune and Biogen extended their collaboration in 2010 by executing an agreement granting worldwide exclusive rights to three immunotherapy programs with human monoclonal antibodies targeting alpha-synuclein, tau and TDP-43. The three targets are thought to play central roles in Parkinson’s disease, taupoathies and fronto-temporal dementia. The program on Parkinson's disease (BIIB054) is currently in Phase 1 clinical testing.
Neurimmune’s current out-licensing opportunities at an advanced stage include programs for transthyretin amyloidosis, type-2 diabetes and amyotrophic lateral sclerosis (ALS).